Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Eli Lilly Drug Patent Portfolio

Eli Lilly owns 16 orange book drugs protected by 60 US patents with Foundayo having the least patent protection, holding only 1 patent. And Retevmo with maximum patent protection, holding 12 patents. Given below is the list of Eli Lilly's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12295987 Method of using a GIP/GLP1 co-agonist for diabetes 30 Dec, 2041
Active
US12071423 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate 06 Jul, 2040
Active
US12343382 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
Active
US12616740 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
Active
US12453758 Method Of Using A Gip/Glp1 Co-Agonist For Diabetes 22 Jul, 2039
Active
US10654866 Selective Estrogen Receptor Degraders 11 Jul, 2039
Active
US11117902 Selective Estrogen Receptor Degraders 11 Jul, 2039
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
Active
US12453755 Gip/Glp1 Agonist Compositions 14 Jun, 2039
Active
US12453756 Gip/Glp1 Agonist Compositions 14 Jun, 2039
Active
US12629404 Gip/Glp1 Agonist Compositions 14 Jun, 2039
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
Active
US10584124 Crystalline Forms 10 Apr, 2039
Active
US10786489 Formulations Of 6-(2-Hydroxy-2-Methylpropxy)-4-(6-(6-((6-Methoxypyridin-3-Yl)Methyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)Pyridin-3-Yl)Pyrazolo[1,5-A]Pyridine-3-Carbonitrile 10 Apr, 2039
Active
US12138250 Formulations Of 6-(2-Hydroxy-2-Methylpropoxy)-4-(6-(6-((6-Methoxypyridin-3-Yl)Methyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)Pyridin-3-Yl)Pyrazolo[1,5-A]Pyridine-3-Carbonitrile 10 Apr, 2039
Active
US10584124 Crystalline forms 10 Oct, 2038
Active
US10786489 Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile 10 Oct, 2038
Active
US12138250 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10 Oct, 2038
Active
US10112942 Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors 10 Apr, 2038
Active
US10137124 Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors 10 Apr, 2038
Active
US10172851 Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors 10 Apr, 2038
Active
US11053214 Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists 05 Dec, 2037
Active
US10112942 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active
US10137124 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active
US10172851 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active
USRE50455 26 Sep, 2037
Active
US9474780 GIP and GLP-1 co-agonist compounds 13 May, 2036
Active
US11045474 Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections 30 Nov, 2032
Active
US9089574 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections 30 Nov, 2032
Active
US8158616 Azetidine and cyclobutane derivatives as JAK inhibitors 31 May, 2032
Active
US11806555 Methods for treating hair loss disorders 02 Nov, 2031
Active
US9737469 Methods for treating hair loss disorders 02 Nov, 2031
Active
US7855211 Protein kinase inhibitors 28 Sep, 2031
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
Active
US12257246 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide 07 Jul, 2030
Active
US8420629 Azetidine and cyclobutane derivatives as JAK inhibitors 10 Mar, 2029
Active
US7423050 Pyridinoylpiperidines as 5-HT1F agonists 17 Feb, 2028
Active
US8435944 Method and composition for transdermal drug delivery 27 Sep, 2027
Active
US8419307 Spreading implement 26 Feb, 2027
Active
US8807861 Spreading implement 26 Feb, 2027
Active
US9289586 Spreading implement 26 Feb, 2027
Active
US8993520 Method and composition for transdermal drug delivery 02 Jun, 2026 Expired
US9180194 Method and composition for transdermal drug delivery 02 Jun, 2026 Expired
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024 Expired
US8784878 Transdermal delivery rate control using amorphous pharmaceutical compositions 13 Jul, 2023 Expired
US8748459 Pyridinoylpiperidines as 5-HT1F agonists 27 Mar, 2023 Expired
US6821975 Beta-carboline drug products 19 May, 2021 Expired
US6821975 Beta-carboline drug products 19 Nov, 2020 Expired
US7182958 β-carboline pharmaceutical compositions 26 Oct, 2020 Expired
US7182958 β-carboline pharmaceutical compositions 26 Apr, 2020 Expired
US6034054 Stable insulin formulations 11 Jun, 2018 Expired
US6551992 Stable insulin formulations 11 Jun, 2018 Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 May, 2018 Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 Nov, 2017 Expired
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017 Expired
US6299900 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017 Expired
US6818226 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017 Expired
US6923983 Transdermal delivery of hormones 19 Feb, 2017 Expired
US8071075 Dermal penetration enhancers and drug delivery systems involving the same 19 Feb, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Eli Lilly.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 26 Jan, 2026 US8748459
Payment of Maintenance Fee, 12th Year, Large Entity 21 Jan, 2026 US8807861
Initial letter Re: PTE Application to regulating agency 11 Dec, 2025 US10654866
Patent eCofC Notification 25 Nov, 2025 US12343382
Mail Patent eCofC Notification 25 Nov, 2025 US12343382
Email Notification 25 Nov, 2025 US12343382
Recordation of Patent eCertificate of Correction 25 Nov, 2025 US12343382
Recordation of Patent eCertificate of Correction 25 Nov, 2025 US12343382
Mail Patent eCofC Notification 25 Nov, 2025 US12343382
Email Notification 25 Nov, 2025 US12343382
Patent eCofC Notification 25 Nov, 2025 US12343382
Email Notification 25 Nov, 2025 US12343382
Mail Patent eCofC Notification 25 Nov, 2025 US12343382
Email Notification 25 Nov, 2025 US12343382
Recordation of Patent eCertificate of Correction 25 Nov, 2025 US12343382


Eli Lilly's Drug Patent Litigations

Eli Lilly's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 13, 2015, against patent number US7182958. The petitioner Actelion Pharmaceuticals Ltd, challenged the validity of this patent, with ICOS Corporation et al. as the respondent. Click below to track the latest information on how companies are challenging Eli Lilly's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9474780 August, 2025 Discretionary Denial
(11 Dec, 2025)
Eli Lilly & Co. BPI Labs, LLC et al.
US9474780 May, 2025 Discretionary Denial
(10 Oct, 2025)
Eli Lilly & Co. Empower Clinic Services, LLC. (d/b/a Empower Pharmacy)
US6821975 January, 2015 Final Written Decision
(03 Aug, 2016)
ICOS Corporation et al. Actelion Pharmaceuticals Ltd
US7182958 January, 2015 Final Written Decision
(03 Aug, 2016)
ICOS Corporation et al. Actelion Pharmaceuticals Ltd


Eli Lilly Drug Patents' Oppositions Filed in EPO

Eli Lilly drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 26, 2017, by Müller Fottner Steinecke Rechtsanwalts- Und Patentanwaltspartnerschaft Mbb. This opposition was filed on patent number EP03729716A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11838771A Apr, 2020 Concert Pharmaceuticals, Inc. Granted and Under Opposition
EP06741180A Aug, 2017 Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB Revoked
EP03729716A Apr, 2017 Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB Revoked


Eli Lilly's Family Patents

Eli Lilly drugs have patent protection in a total of 55 countries. It's US patent count contributes only to 19.0% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Eli Lilly:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Eli Lilly and Company NA COMPLETED
(Sep 1, 2026)
PHASE2
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Study of LY3526318 in Healthy Male Japanese Participants Eli Lilly and Company NA WITHDRAWN
(Sep 1, 2026)
PHASE1
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE2
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of LY4257496 in Participants With Cancer (OMNIRAY) Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study of Brenipatide in Participants With Alcohol Use Disorder Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Brenipatide in Participants With Opioid Use Disorder Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study of LY4355756 in Healthy Participants Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight Eli Lilly and Company NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Eli Lilly and Company NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) Eli Lilly and Company NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Abemaciclib (LY2835219) in Healthy Participants Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 Eli Lilly and Company NA RECRUITING
(Aug 1, 2026)
PHASE1
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer Eli Lilly and Company NA RECRUITING
(Aug 1, 2026)
PHASE2
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Eli Lilly and Company NA COMPLETED
(Aug 1, 2026)
PHASE3
A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Aug 1, 2026)
PHASE1
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis Eli Lilly and Company NA COMPLETED
(Jul 1, 2026)
PHASE3
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Eli Lilly and Company NA COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Eli Lilly and Company NA COMPLETED
(Jul 1, 2026)
PHASE1
A Study of Baricitinib (LY3009104) in Children With COVID-19 Eli Lilly and Company NA TERMINATED
(Jul 1, 2026)
PHASE3
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Eli Lilly and Company NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder Eli Lilly and Company NA COMPLETED
(Jul 1, 2026)
PHASE2
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
A Study of LY4515100 in Healthy Participants Eli Lilly and Company NA RECRUITING
(Jul 1, 2026)
PHASE1
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE1
A Study of LY3502970 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE1
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE3
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE2
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE1
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE3
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE3
A Study of LY4175408 in Participants With Advanced Cancer Eli Lilly and Company NA RECRUITING
(Jun 1, 2026)
PHASE1
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity Eli Lilly and Company NA COMPLETED
(May 1, 2026)
PHASE2
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Eli Lilly and Company NA COMPLETED
(May 1, 2026)
PHASE3
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight Eli Lilly and Company NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Eli Lilly and Company NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus Eli Lilly and Company NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1
A Study of Olomorasib (LY3537982) in Healthy Participants Eli Lilly and Company NA COMPLETED
(May 1, 2026)
PHASE1
A Multiple Dose Study of LY3502970 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Apr 15, 2026)
PHASE1
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Apr 15, 2026)
PHASE1
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Apr 1, 2026)
PHASE1
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants Eli Lilly and Company NA COMPLETED
(Apr 1, 2026)
PHASE1
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants Eli Lilly and Company NA COMPLETED
(Apr 1, 2026)
PHASE1
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Eli Lilly and Company NA COMPLETED
(Mar 1, 2026)
PHASE2, PHASE3
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Eli Lilly and Company NA COMPLETED
(Mar 1, 2026)
PHASE3
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Eli Lilly and Company NA COMPLETED
(Mar 1, 2026)
PHASE3
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Eli Lilly and Company NA RECRUITING
(Sep, 2024)
PHASE2
A Study of LY3841136 in Overweight and Obese Participants Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Sep, 2024)
PHASE1
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Eli Lilly and Company NA COMPLETED
(Aug, 2024)
PHASE4
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity Eli Lilly and Company Regeneron Pharmaceuticals RECRUITING
(Aug, 2024)
PHASE2
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Eli Lilly and Company NA COMPLETED
(Jul, 2024)
PHASE3
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul, 2024)
PHASE3
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Eli Lilly and Company NA COMPLETED
(Apr, 2024)
PHASE2
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes Eli Lilly and Company NA COMPLETED
(Jun, 2022)
PHASE1
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Eli Lilly and Company NA COMPLETED
(Jan, 2022)
PHASE3


Eli Lilly Drug List

Given below is the complete list of Eli Lilly's drugs and the patents protecting them.


1. Adcirca

Adcirca is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6821975
(Pediatric)
Beta-carboline drug products 19 May, 2021
(5 years ago)
Expired
US6821975 Beta-carboline drug products 19 Nov, 2020
(5 years ago)
Expired
US7182958
(Pediatric)
β-carboline pharmaceutical compositions 26 Oct, 2020
(5 years ago)
Expired
US7182958 β-carboline pharmaceutical compositions 26 Apr, 2020
(6 years ago)
Expired
US5859006
(Pediatric)
Tetracyclic derivatives; process of preparation and use 21 May, 2018
(8 years ago)
Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 Nov, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adcirca's drug page


2. Axiron

Axiron is protected by 11 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8435944 Method and composition for transdermal drug delivery 27 Sep, 2027
(11 months from now)
Active
US8419307 Spreading implement 26 Feb, 2027
(4 months from now)
Active
US8807861 Spreading implement 26 Feb, 2027
(4 months from now)
Active
US9289586 Spreading implement 26 Feb, 2027
(4 months from now)
Active
US8993520 Method and composition for transdermal drug delivery 02 Jun, 2026
(4 months ago)
Expired
US9180194 Method and composition for transdermal drug delivery 02 Jun, 2026
(4 months ago)
Expired
US8784878 Transdermal delivery rate control using amorphous pharmaceutical compositions 13 Jul, 2023
(3 years ago)
Expired
US6299900 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017
(9 years ago)
Expired
US6818226 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017
(9 years ago)
Expired
US6923983 Transdermal delivery of hormones 19 Feb, 2017
(9 years ago)
Expired
US8071075 Dermal penetration enhancers and drug delivery systems involving the same 19 Feb, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Axiron's drug page


3. Foundayo

Foundayo is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE50455 26 Sep, 2037
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Foundayo's drug page


4. Humalog Kwikpen

Humalog Kwikpen is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 years ago)
Expired
US6034054 Stable insulin formulations 11 Jun, 2018
(8 years ago)
Expired
US6551992 Stable insulin formulations 11 Jun, 2018
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Kwikpen's drug page


5. Inluriyo

Inluriyo is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10654866 Selective Estrogen Receptor Degraders 11 Jul, 2039
(12 years from now)
Active
US11117902 Selective Estrogen Receptor Degraders 11 Jul, 2039
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inluriyo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Mounjaro

Mounjaro is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12295987 Method of using a GIP/GLP1 co-agonist for diabetes 30 Dec, 2041
(15 years from now)
Active
US12343382 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US12616740 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(12 years from now)
Active
US12453755 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US12453756 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US12629404 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 13 May, 2036
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro's drug page


7. Mounjaro (autoinjector)

Mounjaro (autoinjector) is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12295987 Method of using a GIP/GLP1 co-agonist for diabetes 30 Dec, 2041
(15 years from now)
Active
US12343382 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US12616740 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(12 years from now)
Active
US12453755 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US12453756 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US12629404 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 13 May, 2036
(9 years from now)
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
(4 years from now)
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro (autoinjector)'s drug page


8. Mounjaro Kwikpen

Mounjaro Kwikpen is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12295987 Method of using a GIP/GLP1 co-agonist for diabetes 30 Dec, 2041
(15 years from now)
Active
US12343382 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US12616740 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 13 May, 2036
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro Kwikpen's drug page


9. Olumiant

Olumiant is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11045474 Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections 30 Nov, 2032
(6 years from now)
Active
US9089574 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections 30 Nov, 2032
(6 years from now)
Active
US8158616 Azetidine and cyclobutane derivatives as JAK inhibitors 31 May, 2032
(5 years from now)
Active
US11806555 Methods for treating hair loss disorders 02 Nov, 2031
(5 years from now)
Active
US9737469 Methods for treating hair loss disorders 02 Nov, 2031
(5 years from now)
Active
US8420629 Azetidine and cyclobutane derivatives as JAK inhibitors 10 Mar, 2029
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olumiant's drug page


10. Prozac

Prozac is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prozac's drug page


11. Retevmo

Retevmo is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10584124
(Pediatric)
Crystalline Forms 10 Apr, 2039
(12 years from now)
Active
US10786489
(Pediatric)
Formulations Of 6-(2-Hydroxy-2-Methylpropxy)-4-(6-(6-((6-Methoxypyridin-3-Yl)Methyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)Pyridin-3-Yl)Pyrazolo[1,5-A]Pyridine-3-Carbonitrile 10 Apr, 2039
(12 years from now)
Active
US12138250
(Pediatric)
Formulations Of 6-(2-Hydroxy-2-Methylpropoxy)-4-(6-(6-((6-Methoxypyridin-3-Yl)Methyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)Pyridin-3-Yl)Pyrazolo[1,5-A]Pyridine-3-Carbonitrile 10 Apr, 2039
(12 years from now)
Active
US10584124 Crystalline forms 10 Oct, 2038
(11 years from now)
Active
US10786489 Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile 10 Oct, 2038
(11 years from now)
Active
US12138250 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile 10 Oct, 2038
(11 years from now)
Active
US10112942
(Pediatric)
Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors 10 Apr, 2038
(11 years from now)
Active
US10137124
(Pediatric)
Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors 10 Apr, 2038
(11 years from now)
Active
US10172851
(Pediatric)
Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors 10 Apr, 2038
(11 years from now)
Active
US10112942 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(10 years from now)
Active
US10137124 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(10 years from now)
Active
US10172851 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retevmo's drug page


12. Reyvow

Reyvow is protected by 5 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12071423 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate 06 Jul, 2040
(13 years from now)
Active
US11053214 Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists 05 Dec, 2037
(11 years from now)
Active
US12257246 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide 07 Jul, 2030
(3 years from now)
Active
US7423050 Pyridinoylpiperidines as 5-HT1F agonists 17 Feb, 2028
(1 year, 3 months from now)
Active
US8748459 Pyridinoylpiperidines as 5-HT1F agonists 27 Mar, 2023
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reyvow's drug page


13. Verzenio

Verzenio is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7855211 Protein kinase inhibitors 28 Sep, 2031
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verzenio's drug page


14. Zepbound

Zepbound is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12343382 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US12453758 Method Of Using A Gip/Glp1 Co-Agonist For Diabetes 22 Jul, 2039
(12 years from now)
Active
US12616740 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(12 years from now)
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
(12 years from now)
Active
US12453756 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US12629404 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 13 May, 2036
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound's drug page


15. Zepbound (autoinjector)

Zepbound (autoinjector) is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12343382 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US12453758 Method Of Using A Gip/Glp1 Co-Agonist For Diabetes 22 Jul, 2039
(12 years from now)
Active
US12616740 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(12 years from now)
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
(12 years from now)
Active
US12453756 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US12629404 Gip/Glp1 Agonist Compositions 14 Jun, 2039
(12 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 13 May, 2036
(9 years from now)
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
(4 years from now)
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound (autoinjector)'s drug page


16. Zepbound Kwikpen

Zepbound Kwikpen is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12343382 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US12453758 Method Of Using A Gip/Glp1 Co-Agonist For Diabetes 22 Jul, 2039
(12 years from now)
Active
US12616740 Methods Of Using A Gip/Glp1 Co-Agonist For Therapy 22 Jul, 2039
(12 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 13 May, 2036
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound Kwikpen's drug page